title: Synergism of H2 histamine receptor antagonists with alpha-interferon to inhibit the growth of leukemic and normal hematopoietic progenitors.
authors.affiliation: Institute of Hematology, Chaim Sheba Medical Center, Tel Hashomer and Sackler School of Medicine, Tel-Aviv University Israel.
authors.forename: D
authors.initials: D
authors.lastname: Douer
authors.forename: I
authors.initials: I
authors.lastname: Ben-Bassat
authors.forename: A
authors.initials: A
authors.lastname: Kneller
authors.forename: S D
authors.initials: SD
authors.lastname: Chitayat
authors.forename: N
authors.initials: N
authors.lastname: Shaked
authors.forename: S
authors.initials: S
authors.lastname: Salzberg
authors.forename: B
authors.initials: B
authors.lastname: Ramot
mesh_terms: D002455:Cell Division / Q000187:drug effects; D002927:Cimetidine / Q000494:pharmacology; D003864:Depression, Chemical; D004354:Drug Screening Assays, Antitumor; D004357:Drug Synergism; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000187:drug effects*; D006635:Histamine H2 Antagonists / Q000494:pharmacology*; D006801:Humans; D007370:Interferon Type I / Q000494:pharmacology*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000473:pathology*; D014411:Neoplastic Stem Cells / Q000187:drug effects* / Q000473:pathology; D011994:Recombinant Proteins; D014407:Tumor Cells, Cultured / Q000187:drug effects
chemical_list: D006635:Histamine H2 Antagonists; D007370:Interferon Type I; D011994:Recombinant Proteins; D002927:Cimetidine